

Ezio Giacobini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10452219/publications.pdf>

Version: 2024-02-01

103
papers

7,537
citations

93792

39
h-index

62345

84
g-index

105
all docs

105
docs citations

105
times ranked

9225
citing authors

#	ARTICLE	IF	CITATIONS
1	Reimagining cholinergic therapy for Alzheimer's disease. <i>Brain</i> , 2022, 145, 2250-2275.	3.7	50
2	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	2.0	27
3	β -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	3.0	16
4	Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors. <i>Current Alzheimer Research</i> , 2018, 15, 1077-1084.	0.7	61
5	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1917-1933.	3.7	1,008
6	Sex differences in Alzheimer disease – the gateway to precision medicine. <i>Nature Reviews Neurology</i> , 2018, 14, 457-469.	4.9	573
7	The biomarker-based diagnosis of Alzheimer's disease. – ethical and societal issues. <i>Neurobiology of Aging</i> , 2017, 52, 132-140.	1.5	39
8	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , 2017, 16, 661-676.	4.9	464
9	A Study of A β Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls. <i>Neurodegenerative Diseases</i> , 2016, 16, 398-406.	0.8	14
10	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
11	A new roadmap for drug development for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 156-156.	21.5	54
12	Alzheimer disease therapy – moving from amyloid- β to tau. <i>Nature Reviews Neurology</i> , 2013, 9, 677-686.	4.9	421
13	Phenserine Efficacy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1201-1208.	1.2	62
14	Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 303-325.	1.2	125
15	One Hundred Years after the Discovery of Alzheimer's Disease. A Turning Point for Therapy?. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 37-52.	1.2	89
16	Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. , 2006, , 235-264.		35
17	Cholinesterase inhibitors: new roles and therapeutic alternatives. <i>Pharmacological Research</i> , 2004, 50, 433-440.	3.1	482
18	Drugs that target cholinesterases. , 2004, , 11-36.		17

#	ARTICLE	IF	CITATIONS
19	Cholinesterases: new roles in brain function and in Alzheimer's disease. <i>Neurochemical Research</i> , 2003, 28, 515-522.	1.6	294
20	Cholinergic function and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S1-S5.	1.3	245
21	Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. <i>Journal of Neural Transmission</i> , 2002, 109, 1053-1065.	1.4	196
22	Do Cholinesterase Inhibitors Have Disease-Modifying Effects in Alzheimer's Disease?. <i>CNS Drugs</i> , 2001, 15, 85-91.	2.7	66
23	Selective Inhibitors of Butyrylcholinesterase. <i>Drugs and Aging</i> , 2001, 18, 891-898.	1.3	128
24	Cholinesterase inhibitors stabilize Alzheimer disease. , 2000, 25, 1185-1190.		57
25	Cholinesterase Inhibitors Stabilize Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 321-327.	1.8	108
26	Metrifonate: A Cholinesterase Inhibitor for Alzheimer's Disease Therapy. <i>CNS Neuroscience & Therapeutics</i> , 1999, 5, 13-26.	4.0	5
27	Cholinergic foundations of Alzheimer's disease therapy. <i>Journal of Physiology (Paris)</i> , 1998, 92, 283-287.	2.1	53
28	Invited Review Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. <i>Neurochemistry International</i> , 1998, 32, 413-419.	1.9	196
29	Pharmacological Basis of Cholinergic Therapy in Alzheimer Disease. , 1998, , 153-157.		0
30	From Molecular Structure to Alzheimer Therapy.. <i>The Japanese Journal of Pharmacology</i> , 1997, 74, 225-241.	1.2	88
31	Metrifonate. <i>Drugs and Aging</i> , 1997, 11, 497.	1.3	2
32	From Molecular Structure to Alzheimer Therapy. <i>The Japanese Journal of Pharmacology</i> , 1997, 74, 225-241.	1.2	11
33	Nicotinic Agonist Modulation of Neurotransmitter Levels in the Rat Frontoparietal Cortex. <i>The Japanese Journal of Pharmacology</i> , 1997, 74, 139-146.	1.2	5
34	Cholinesterase Inhibitors Do More than Inhibit Cholinesterase. , 1997, , 187-204.		17
35	Alzheimer Disease. <i>Advances in Experimental Medicine and Biology</i> , 1997, , 235-245.	0.8	16
36	Chapter 30 New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors?. <i>Progress in Brain Research</i> , 1996, 109, 311-323.	0.9	28

#	ARTICLE	IF	CITATIONS
37	A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. <i>Neurochemical Research</i> , 1996, 21, 1181-1186.	1.6	40
38	Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. <i>NeuroReport</i> , 1995, 6, 633-636.	0.6	162
39	Metrifonate effects on acetylcholine and biogenic amines in rat cortex. <i>Neurochemical Research</i> , 1995, 20, 1081-1088.	1.6	43
40	5-Fluoronicotine, noranhydroecgonine, and pyridyl-methylpyrrolidine release acetylcholine and biogenic amines in rat cortex in vivo. <i>Neurochemical Research</i> , 1995, 20, 1089-1094.	1.6	13
41	Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex. <i>European Journal of Pharmacology</i> , 1995, 276, 93-99.	1.7	26
42	Cellular Acetylcholine Receptor Expression in the Brain of Patients with Alzheimer's and Parkinson's Dementia. <i>Advances in Behavioral Biology</i> , 1995, , 63-67.	0.2	3
43	Alzheimer Disease: Major Neurotransmitter Deficits. Can they be Corrected?. <i>Advances in Behavioral Biology</i> , 1995, , 429-436.	0.2	0
44	Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex. <i>Drug Development Research</i> , 1994, 31, 108-119.	1.4	30
45	Therapy for Alzheimer's disease. <i>Molecular Neurobiology</i> , 1994, 9, 115-118.	1.9	11
46	Trimethylsilylated trifluoromethyl ketones, a novel class of acetylcholinesterase inhibitors: biochemical and pharmacological profile of MDL 73,745. <i>Biochemical Society Transactions</i> , 1994, 22, 758-763.	1.6	22
47	Second and Third Generation Cholinesterase Inhibitors: From Preclinical Studies to Clinical Efficacy. , 1994, , 155-171.		25
48	Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition. <i>Neuroscience Letters</i> , 1993, 158, 205-208.	1.0	27
49	Chapter 55: Pharmacotherapy of Alzheimer disease: new drugs and novel strategies. <i>Progress in Brain Research</i> , 1993, 98, 447-454.	0.9	30
50	Nicotine, Parkinson's and Alzheimer's Disease. <i>Reviews in the Neurosciences</i> , 1992, 3, 25-44.	1.4	22
51	Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. <i>Brain Research</i> , 1992, 589, 307-312.	1.1	40
52	Preferential inhibition of acetylcholinesterase molecular forms in rat brain. <i>Neurochemical Research</i> , 1992, 17, 489-495.	1.6	43
53	Cholinomimetic Replacement of Cholinergic Function in Alzheimer Disease. <i>Advances in Behavioral Biology</i> , 1992, , 19-34.	0.2	6
54	Muscarinic cholinergic neurons in the frontal cortex in Alzheimer's disease. <i>Brain Research Bulletin</i> , 1991, 27, 631-636.	1.4	38

#	ARTICLE	IF	CITATIONS
55	Nicotinic cholinergic neurons of the frontal cortex are reduced in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1991, 12, 259-262.	1.5	153
56	Nucleus basalis lesions decrease α - and β -bungarotoxins binding in rat cortex. <i>NeuroReport</i> , 1991, 2, 177-180.	0.6	5
57	Cellular Distribution and Expression of Cortical Acetylcholine Receptors in Aging and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 189-192.	1.8	20
58	The Second Generation of Cholinesterase Inhibitors: Pharmacological Aspects. , 1991, , 247-262.		28
59	Cerebrospinal fluid choline levels are decreased in Parkinson's disease. <i>Annals of Neurology</i> , 1990, 27, 683-685.	2.8	21
60	Effects of metrifonate, a long-acting cholinesterase inhibitor, in alzheimer disease: Report of an open trial. <i>Drug Development Research</i> , 1990, 19, 425-434.	1.4	85
61	Chapter 34 The cholinergic system in Alzheimer disease. <i>Progress in Brain Research</i> , 1990, 84, 321-332.	0.9	82
62	Choline levels are increased in cerebrospinal fluid of Alzheimer patients. <i>Neurobiology of Aging</i> , 1989, 10, 45-50.	1.5	36
63	Chapter 33 The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer. <i>Progress in Brain Research</i> , 1989, 79, 335-343.	0.9	39
64	Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects. <i>Drug Development Research</i> , 1988, 12, 163-195.	1.4	189
65	Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: Can acetylcholine levels in the brain be improved in alzheimer's disease?. <i>Drug Development Research</i> , 1988, 14, 235-246.	1.4	21
66	Brain morphological measures and CSF acetylcholine in Alzheimer dementia. <i>Psychiatry Research</i> , 1988, 23, 111-114.	1.7	2
67	Cerebrospinal fluid choline, and acetylcholinesterase activity in familial vs. non-familial Alzheimer's disease patients. <i>Archives of Gerontology and Geriatrics</i> , 1988, 7, 111-117.	1.4	12
68	Chapter 8 Carbonic Anhydrase: The First Marker of Glial Development. <i>Current Topics in Developmental Biology</i> , 1987, 21, 207-215.	1.0	7
69	Aging of cholinergic synapses in the avian iris. Part I "Biochemical studies. <i>Neurobiology of Aging</i> , 1987, 8, 123-129.	1.5	4
70	Brain Acetylcholine " A View From the Cerebrospinal Fluid. , 1987, , 85-101.		7
71	Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease.. <i>Keio Journal of Medicine</i> , 1987, 36, 381-391.	0.5	18
72	Experimental maternal hyperpipercolatemia decreases DNA in the mouse brain. <i>International Journal of Developmental Neuroscience</i> , 1986, 4, 113-118.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Brain acetylcholine—a view from the cerebrospinal fluid (CSF). <i>Neurobiology of Aging</i> , 1986, 7, 392-396.	1.5	12
74	Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat. <i>Neurochemical Research</i> , 1986, 11, 1037-1048.	1.6	61
75	Development of Peripheral Parasympathetic Neurons and Synapses. , 1986, , 29-67.		0
76	Distribution of pipecolic acid and proline in the developing rat brain and peripheral organs. <i>International Journal of Developmental Neuroscience</i> , 1985, 3, 379-384.	0.7	4
77	Quantitative determination and regional distribution of pipecolic acid in rodent brain. <i>Neurochemical Research</i> , 1984, 9, 1559-1569.	1.6	12
78	Biochemical Differentiation and Development of Autonomic Neurons and Synapses. , 1983, , 467-488.		2
79	Aging of Autonomic Synapses. <i>Advances in Cellular Neurobiology</i> , 1982, 3, 173-214.	1.0	7
80	Development and aging of noradrenergic cell bodies and axon terminals in the chicken. <i>Journal of Neuroscience Research</i> , 1981, 6, 621-641.	1.3	23
81	³ H-thymidine long survival autoradiography as a method for dating the time of neuronal origin in the chick embryo: The locus coeruleus and cerebellar Purkinje cells. <i>Journal of Comparative Neurology</i> , 1981, 203, 257-267.	0.9	39
82	Time course of appearance of α -bungarotoxin binding sites during development of chick ciliary ganglion and iris. <i>Neurochemical Research</i> , 1978, 3, 465-478.	1.6	76
83	Acetylcholinesterase activity in ventricular and cisternal csf of dogs: Effect of chlorpromazine. <i>Journal of Neuroscience Research</i> , 1978, 3, 335-339.	1.3	46
84	VALIDITY OF SINGLE NEURON CHEMICAL ANALYSIS. , 1978, , 3-17.		2
85	Activity of Enzymes Related to Neurotransmission in Neuronal and Glial Fractions. <i>International Journal of Neuroscience</i> , 1973, 5, 87-90.	0.8	22
86	Dopa—decarboxylase in Autonomic and Sensory Ganglia of the Cat. <i>Acta Physiologica Scandinavica</i> , 1971, 82, 209-217.	2.3	13
87	Catechol—Methyltransferase in Autonomic and Sensory Ganglia of the Cat. <i>Acta Physiologica Scandinavica</i> , 1969, 75, 523-529.	2.3	9
88	Pentose Shunt Enzymes in the Crustacean Stretch Receptor Neuron after Impulse Activity. <i>Acta Physiologica Scandinavica</i> , 1968, 73, 255-256.	2.3	11
89	Monoamine Oxidase in Sympathetic Ganglia of the Cat. <i>Acta Physiologica Scandinavica</i> , 1968, 74, 513-520.	2.3	34
90	CHOLINERGIC AND ADRENERGIC CELLS IN SYMPATHETIC GANGLIA. <i>Annals of the New York Academy of Sciences</i> , 1967, 144, 646-659.	1.8	15

#	ARTICLE	IF	CITATIONS
91	Cholinesterase Activity in Innervated and Denervated Sympathetic Ganglion Cells of the Cat. Acta Physiologica Scandinavica, 1967, 69, 355-361.	2.3	29
92	Intracellular Variations of Na and K in Isolated Nerve Cells. Acta Physiologica Scandinavica, 1967, 71, 391-400.	2.3	11
93	Variations of Glycolytic Intermediates, Phosphate Compounds and Pyridine Nucleotides after Prolonged Stimulation of an Isolated Crustacean Neurone. Acta Physiologica Scandinavica, 1966, 66, 49-57.	2.3	24
94	The Action of Tricarboxylic Acid Cycle Intermediates and Glutamate on the Impulse Activity and Respiration of the Crayfish Stretch Receptor Neurone. Acta Physiologica Scandinavica, 1966, 66, 58-66.	2.3	11
95	Pyruvate, Glutamate and Tricarboxylic Acid Intermediates in the Crustacean Stretch Receptor Neurone after Prolonged Impulse Activity. Acta Physiologica Scandinavica, 1966, 66, 247-248.	2.3	8
96	Use of microgasometric techniques in pharmacological studies. Biochemical Pharmacology, 1962, 9, 155-164.	2.0	5
97	A CYTOCHEMICAL STUDY OF THE LOCALIZATION OF CARBONIC ANHYDRASE IN THE NERVOUS SYSTEM. Journal of Neurochemistry, 1962, 9, 169-177.	2.1	247
98	Cholinesterase in Muscles: A Histochemical and Microgasometric Study. Acta Pharmacologica Et Toxicologica, 1960, 17, 94-105.	0.0	28
99	Quantitative Determination of Cholinesterase in Individual Spinal Ganglion Cells. Acta Physiologica Scandinavica, 1959, 45, 238-254.	2.3	40
100	Determination of $\hat{\alpha}$ Cholinesterase in the Cellular Components of Neurones. Acta Physiologica Scandinavica, 1959, 45, 311-327.	2.3	21
101	QUANTITATIVE DETERMINATION OF CHOLINESTERASE IN INDIVIDUAL SYMPATHETIC CELLS. Journal of Neurochemistry, 1957, 1, 234-244.	2.1	57
102	Quantitative Determination of Acetylcholinesterase Activity in Individual Nerve Cells. Nature, 1956, 177, 185-186.	13.7	37
103	Histochemical Demonstration of AChE Activity in Isolated Nerve Cells. Acta Physiologica Scandinavica, 1956, 36, 276-290.	2.3	60